Results 11 to 20 of about 17,271 (194)
Prescription pattern of abiraterone in Brazil - a survey of medical oncologists
Introduction: Abiraterone acetate is widely used for the treatment of prostate cancer. In Brazil, the label dose is not affordable to most patients due to its elevated cost.
João Pedro Homse-Netto +4 more
doaj +2 more sources
The anticancer agent abiraterone suffers from an extensive positive food effect after oral intake of the prodrug abiraterone acetate (Zytiga). The underlying processes determining postprandial abiraterone absorption were investigated in this study.
Marlies Braeckmans +2 more
exaly +3 more sources
Effect of Dexamethasone on Abiraterone Pharmacokinetics in Mice: Determined by LC/MS Analysis
Background: Abiraterone acetate is a cytochrome P450 17A1 (CYP17A1) inhibitor that is indicated for use in both castration-resistant and castration-sensitive prostate cancer patients.
Subrata Deb +4 more
doaj +2 more sources
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Elahe A Mostaghel Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Abstract: Androgen deprivation therapy remains the single most effective treatment for the initial therapy of advanced prostate cancer, but is ...
Mostaghel EA
doaj +1 more source
Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus ...
Pedro Nazareth Aguiar Jr. +6 more
doaj +2 more sources
Abiraterone acetate 1000 mg/day, combined with prednisone 5 mg PO twice daily, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
E. David Crawford +4 more
doaj +2 more sources
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. [PDF]
Background While the cardiovascular risks of androgen receptor pathway inhibitors have been studied, they were seldom compared directly. This study compares the risks of major adverse cardiovascular events (MACE) between enzalutamide and abiraterone ...
Jeremy Man Ho Hui +12 more
core +3 more sources
Correction to "Chidamide (a Histone Deacetylase Inhibitor) Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Phase Ib Trial". [PDF]
MedComm, Volume 7, Issue 11, November 2026.
europepmc +2 more sources
Abiraterone acetate is a prodrug of abiraterone used in combination with prednisone as a standard therapeutic strategy for hormone-resistant prostate cancer (mCRPC).
Yuanfen Liu +5 more
doaj +1 more source
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. [PDF]
BackgroundDocetaxel is an established first-line therapy to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved for use after docetaxel failure, with improved survival. National Institute for
Lixian Zhong +8 more
doaj +1 more source

